LA JOLLA, CALIF. –
In a video interview, meeting cochair, PhD, of Columbia University Medical Center in New York discussed a few presentations that addressed epigenetics in T-cell lymphomas.
, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore gave the meeting’s keynote address, which focused on the idea that epigenetic therapy can enhance immune checkpoint therapy.
, of Columbia University Medical Center, presented data that suggest romidepsin and other histone deacetylase inhibitors fight cutaneous T-cell lymphoma via epigenetic effects on gene expression, as well as DNA damage.
And Enrica Marchi, MD, PhD, of Columbia University Medical Center discussed the use of epigenetic-based combination therapies to improve responses in T-cell lymphomas.
The T-cell Lymphoma Forum is organized by Jonathan Wood & Associates, which is owned by the same company as this news organization.